Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 106Neoplasms 14Neoplasm Metastasis 14Carcinoma, Non-Small-Cell Lung 4Advanced Breast Cancer 4Hereditary Sensory and Autonomic Neuropathies 3Recurrence 2Prostatic Neoplasms 2Ovarian Neoplasms 2Multiple Endocrine Neoplasia Type 1 2Endometrial Neoplasms 2Breast Neoplasms, Male 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urologic Neoplasms 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Solid Malignancies 1Recurrent Uterine Corpus Carcinoma 1Neoplasms by Site 1Lymphoma, Non-Hodgkin 1Lymphoma 1Locally Advanced (Inoperable) or Metastatic Breast Cancer 1Lethal Congenital Contracture Syndrome 2 1Hyperglycemia 1Hormone Receptor Positive HER-2 Negative Breast Cancer 1Hormone Receptor Positive Breast Cancer 1HER2-positive Breast Cancer 1Female Breast Carcinoma 1Exanthema 1

Interventions

palbociclib 1Letrozole 1Fulvestrant 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Estrogen Receptor-positive Breast Cancer × Fulvestrant × Clear all
NCT03633331 2026-04-29

Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer

Alliance for Clinical Trials in Oncology

Phase 2 Completed
93 enrolled 16 charts
Breast

Estrogen Receptor-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡